- Home
- RDCM vs PRLD Comparison
RDCM vs PRLD Comparison
Compare RDCM & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RDCM | PRLD |
|---|---|---|
| Founded | 1985 | 2016 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 205.1M | 218.0M |
| IPO Year | 1999 | 2020 |
Fundamental Metrics
Financial Performance| Metric | RDCM | PRLD |
|---|---|---|
| Price | $12.14 | $4.08 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $18.00 | $4.67 |
| AVG Volume (30 Days) | 43.3K | ★ 211.0K |
| Earning Date | 05-13-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 23.21 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $12,140,000.00 |
| Revenue This Year | $11.50 | $320.10 |
| Revenue Next Year | $9.74 | $100.00 |
| P/E Ratio | $16.35 | ★ N/A |
| Revenue Growth | N/A | ★ 73.43 |
| 52 Week Low | $10.20 | $0.66 |
| 52 Week High | $15.14 | $4.82 |
Technical Indicators
Market Signals| Indicator | RDCM | PRLD |
|---|---|---|
| Relative Strength Index (RSI) | 54.23 | 65.61 |
| Support Level | $10.65 | $1.02 |
| Resistance Level | $13.59 | N/A |
| Average True Range (ATR) | 0.61 | 0.40 |
| MACD | 0.09 | 0.09 |
| Stochastic Oscillator | 59.36 | 68.02 |
Price Performance
Historical ComparisonAbout RDCM Radcom Ltd.
Radcom Ltd Ltd is engaged in providing network intelligence, 5G ready cloud-native, network intelligence solutions for telecom operators transitioning to 5G. The company has a network intelligence solution for 5G namely Radcom ACE. Its products consist of Radcom Network Visibility, Radcom Service Assurance, and Radcom Network Insights. It has offices in Israel, the United States, Brazil, and India. Key revenue is derived from sales in North America.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.